Recapitulation of embryonic pancreatic development has enabled development of methods
for in vitro islet cell differentiation using human pluripotent stem cells (hPSCs), which have …

Islet dysfunction is central in type 2 diabetes and full-blown type 2 diabetes develops first
when the beta cells lose their ability to secrete adequate amounts of insulin in response to …

Pancreatic islet cells derived from human pluripotent stem cells hold great promise for
modeling and treating diabetes. Differences between stem-cell-derived and primary islets …

Human embryonic stem cells (hESCs) provide opportunities for cell replacement therapy of
insulin-dependent diabetes. Therapeutic quantities of human stem cell-derived islets (SC …

Pancreatic islets regulate blood glucose homeostasis through the controlled release of
insulin; however, current metabolic models of glucose-sensitive insulin secretion are …

Insulin injection is currently the main therapy for type 1 diabetes (T1D) or late stage of
severe type 2 diabetes (T2D). Human pancreatic islet transplantation confers a significant …

Diabetes results from an inadequate number of insulin-producing human beta cells. There is
currently no clinically available effective means to restore beta cell mass in millions of …

The ability to maintain normoglycaemia, through glucose-sensitive insulin release, is a key
aspect of postnatal beta cell function. However, terminally differentiated beta cell identity …

Insulin represents a life-saving treatment in patients with type 1 diabetes, and technological
advancements have improved glucose control in an increasing number of patients. Despite …

Aims/hypothesis Pancreatic islets depend on cytosolic calcium (Ca2+) to trigger the
secretion of glucoregulatory hormones and trigger transcriptional regulation of genes …